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syndrome in schizophrenia: a review of
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Abstract
Background: There is conflicting evidence on the association between antipsychotic polypharmacy and metabolic
syndrome in schizophrenia. We conducted a review of published systematic reviews to evaluate evidence on the
association between metabolic syndrome (diabetes, hypertension, and hyperlipidaemia) and exposure to
antipsychotic polypharmacy in schizophrenia.
Methods: We searched five electronic databases, complemented by reference screening, to find systematic reviews
that investigated the association of antipsychotic polypharmacy in schizophrenia with hypertension, diabetes, or
hyperlipidaemia. Selection of reviews, data extraction and review quality were conducted independently by two
people and disagreements resolved by discussion. Results were synthesised narratively.
Results: We included 12 systematic reviews, which reported heterogeneous results, mostly with narrative syntheses
and without pooled data. The evidence was rated as low quality. There was some indication of a possible
protective effect of drug combinations including aripiprazole for diabetes and hyperlipidaemias, compared to other
combinations and/or monotherapy. Only one review reported the association between APP and hypertension. The
most frequently reported combinations of medication included clozapine, possibly representing a sample of
patients with treatment resistant illness. No included review reported results separately by setting (primary or
secondary care).
Conclusions: Further robust studies are needed to elucidate the possible protective effect of aripiprazole. Long-
term prospective studies are required for accurate appraisal of diabetes risk, hypertension and hyperlipidaemia in
patients exposed to antipsychotic polypharmacy.
Keywords: Schizophrenia, Antipsychotics, Diabetes mellitus, Metabolic syndrome
Background
Schizophrenia is a severe mental illness with a preva-
lence of approximately 1% [1].
It is expensive to treat [2] and at least 30% of patients
with this illness experience a poor long-term prognosis,
characterised by residual psychotic symptoms [3], poor
social functioning and a poor quality of life [4]. People
with schizophrenia die on average 20 years earlier than
individuals without this illness and this gap is widening
[5]. One of the possible explanations for the differential
mortality rate is that patients with schizophrenia have an
increased risk of metabolic syndrome such as diabetes,
obesity, hypertension and hypercholesterolemia [6].
Antipsychotic medication is the first line treatment for
schizophrenia [7, 8]. Antipsychotic drugs are effective
for the treatment of the core symptoms of schizophre-
nia, such as auditory hallucinations and delusions. These
drugs can be divided in two main classes: first gener-
ation antipsychotics (FGA or typical antipsychotics) such
as haloperidol and second-generation antipsychotics
(SGA or atypical) such as risperidone, olanzapine and
quetiapine. FGAs are dopamine antagonists acting on
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the three main pathways for this neurotransmitter, while
SGAs have in general, an affinity for both dopamine and
5HT 2 receptors and are thought to be more selective
towards the mesolimbic system [9]. Aripiprazole differs
from other established atypical antipsychotics in being a
partial agonist of dopamine receptors, and is considered
by some authors to be sufficiently distinct to merit clas-
sification as a ‘third generation’ antipsychotic [10].
Schizophrenia is a chronic illness and most patients re-
quire lifelong treatment. Side-effects of antipsychotics
accumulate over time. Long-term treatment with anti-
psychotic medication can increase the risk of diabetes,
hypertension and hyperlipidaemia [11]. This state of
metabolic change leading to an increased risk of cardio-
vascular and metabolic illness is known as metabolic
syndrome. There are several definitions of metabolic
syndrome [12]. The American Heart Association identi-
fies six main components: abdominal obesity, dyslipidae-
mia, increased blood pressure, glucose intolerance and a
pro-inflammatory and pro-thrombotic state [12]. In this
overview, we use the term ‘metabolic syndrome’ to refer
to the occurrence of hyperlipidaemia, diabetes or hyper-
tension which are disorders commonly requiring treat-
ment with medication.
Antipsychotic polypharmacy (APP) is defined as the
simultaneous prescription of more than one anti-
psychotic medication. Patients may be prescribed more
than one antipsychotic when they are deemed resistant
to the effect of a single antipsychotic, they have more
than one psychiatric diagnosis, the clinician is overlap-
ping one medication while another is titrated, or an ef-
fective dose of one antipsychotic cannot be achieved
because of lack of tolerance or side effects [8]. APP is
not actively recommended in current clinical practice
guidelines, yet it is extremely common in clinical prac-
tice, occurring in up to two-thirds of patients with
psychosis [13–16].
APP is controversial because of a lack of clear evi-
dence for treatment efficacy and the possible increased
risk of side-effects over and above side-effects associated
with anti-psychotic monotherapy [8, 17]. Research con-
ducted mostly in secondary-care has produced conflict-
ing evidence on the association between APP and
metabolic syndrome, with some studies suggesting an in-
crease and some a reduction in risk [13, 18, 19].
A scoping review conducted by this group suggested a
need to collate the evidence from systematic reviews on
the link between APP and metabolic syndrome to
facilitate clinical decisions and stimulate new research in
this area.
Aims of the study
To conduct a review of published systematic reviews to
assess the current state of the evidence on the
association between antipsychotic polypharmacy (APP)
used for the management of schizophrenia and meta-
bolic syndrome (defined as diabetes, hypertension, or
hyperlipidaemia).
Methods
This review followed guidance published by the Centre
for Reviews and Dissemination [20]. We wrote a proto-
col for the review with pre-specified objectives, eligibility
criteria and review methods and registered it with
PROSPERO (CRD42017054672) [21].
Inclusion criteria for reviews
We included systematic reviews that reported an investi-
gation of the association between APP and metabolic
syndrome (diabetes, hypertension or hyperlipidaemia) in
adults with schizophrenia treated in any setting. To be
inclusive, we considered any reviews and meta-analysis
reports to be systematic reviews as long as they reported
a systematic search when evaluating the association
between APP and metabolic syndrome.
We excluded reviews that focussed on animal or
laboratory studies only.
Identification and selection of reviews
Five databases (Medline, Embase, Cochrane, PsychInfo
and Web of Science) were searched from inception until
February 2017 to identify relevant reviews, using a sys-
tematic review filter. The search strategy for Medline is
reported in the web appendix (Additional file 1).
Searches were not limited by language, date, setting or
publication status. An internet search using Google
Scholar and screening reference lists of included publi-
cations were used to identify any additional relevant un-
published reviews. A systematic review filter was applied
along with removal of duplicates to find relevant re-
views. We did not search any regional databases.
Titles and abstracts of all citations from the search
were independently screened by two reviewers and dis-
crepant decisions resolved by discussion. Full text
screening was then undertaken by two reviewers and
disagreements resolved by a third reviewer with experi-
ence in psychopharmacology.
Data extraction and quality assessment of included
reviews
Data extraction and quality assessment were conducted
in duplicate and disagreements resolved by discussion.
We used a standardized data extraction template and
extracted the following items from included reviews:
country of study; funding source; number of studies in-
cluded in review; dates of search; setting (primary/sec-
ondary care); designs of reviewed studies; whether a
meta-analysis was conducted; types of participants,
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intervention, comparator, outcome and definition of out-
come; whether a formal quality/risk of bias assessment
was conducted and its findings; and results or findings
of the review.
We used the validated AMSTAR (A MeaSurement
Tool to Assess systematic Reviews) checklist [22] for
assessing reporting quality of the systematic reviews
included.
Data synthesis
We carried out a narrative synthesis of the included sys-
tematic reviews with findings summarised in the text by
outcome [20].
Analysis of subgroups or subsets
We planned to investigate the effects of the combination
of different classes of antipsychotics, provided that suffi-
cient papers reporting these effects were detected.
Assessment of certainty of evidence
We used the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) framework to as-
sess the certainty of the evidence from the reviews and
the strength of the recommendations [23] This approach
identifies four elements which influence the certainty of
the evidence: study design, study quality (risk of bias),
consistency (between estimates of effect across reviews)
and directness (i.e. applicability of participants, interven-
tions, comparisons and outcomes of included reviews to
the clinical question under review).
Results
The multiple database search located 12,321 citations.
Complementary searching (see web appendix for de-
tails) resulted in 29 further unique citations. Remov-
ing 6341 duplicates and applying the systematic
review filter resulted in 499 references. Thirty-seven
of these were assessed in full text and 12 were in-
cluded. One ongoing review was also identified. (See
the PRISMA flow chart in Fig. 1). This review and
the excluded full text reviews with reasons are re-
ported in web appendix (Additional file 2). The most
common reason for exclusion was lack of any meta-
bolic syndrome outcomes (n = 13) followed by the re-
view not addressing APP (n = 8), and opinion articles
(n = 2). One review did not address schizophrenia.
We also extracted data on BMI from the included
reviews. These additional data are available in a web
appendix (Additional file 3).
Fig. 1 PRISMA flow chart of review selection process
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Description of included reviews
Twelve systematic reviews were included [24–35]. The
numbers of primary studies included in the reviews
ranged from 5 to 72 (median 46), although this number
was not always reported. When this was the case we de-
rived the figure from the tables and forest plots in the
paper. One ongoing Cochrane review was also identified
[36]. All except two reviews reported search dates. Most
were from the date of inception of the databases or, in
one case from 1985. The most recent searches were up
until 2015 in two reviews.
The inclusion criteria in the reviews varied and
methods used for inclusion were often not explicitly de-
scribed. (Table 1). All reviews included diagnosed
schizophrenia patient populations on antipsychotic ther-
apy. APP was compared to antipsychotic monotherapy
in six reviews. The other six did not specify the compari-
son. Outcomes of interest that were reported in the in-
cluded reviews were lipid metabolism markers (8
reviews), diabetes or glucose metabolism markers (3
reviews), and hypertension (1 review).
Only two included reviews provided definitions for the
metabolic outcomes: Mizuno et al. 2014 [29] defined
metabolic outcomes (fasting glucose, HbA1C, Total LDL
(Low density lipoprotein) and HDL (High density lipo-
protein) cholesterol) as ‘at endpoint as defined in indi-
vidual studies’. Young et al. 2015 [25] defined metabolic
syndrome as either the International Diabetes Federation
(IDF) criteria for metabolic syndrome in adults and chil-
dren, or National Cholesterol Education Programme
(NCEP) criteria for metabolic syndrome. Similarly, dysli-
pidaemia was defined as at least one of the followings:
total cholesterol > 200 mg/dL; HDL cholesterol 120 mg/
dL; triglycerides ≥150 mg/dL; treatment for a known
lipid disorder.
No reviews reported useable data for subgroup
analyses.
Quality of included reviews
All the included reviews were considered at high risk of
bias based on AMSTAR assessments (21). For one re-
view (33) we could not locate a full text or a protocol
and so assessments were based on abstract information
alone.
In total, four reviews reported an a priori design, only
two performed study selection and data extraction in du-
plicate, six performed a comprehensive literature search,
and only five included both published and unpublished
studies irrespective of language of publication.
None of the reviews provided a list of both included
and excluded studies and only six provided characteris-
tics of included studies as required by the AMSTAR cri-
teria. Four assessed and documented the scientific
quality of included studies and three of these used the
scientific quality of the included studies appropriately in
formulating conclusions.
Five reviews used appropriate methods to combine
studies in a meta-analysis, but none provided a conflict
of interest statement or funding sources of included
studies, although most did report this for the authors.
Most of the review authors were supported by one or
more pharmaceutical companies.
Although none of the reviews were judged to be at low
risk of bias, in our opinion reviews by Mizuno et al. and
Anonymous et al. were more reliable because these used
an a priori protocol, duplicate selection and extraction,
and comprehensive searching without limits and also
considered the study quality in their findings and con-
clusions. (See Table 2).
Metabolic syndrome
Metabolic syndrome was an outcome in two reviews
(Table 3). Young et al. [25] reported an association be-
tween APP and metabolic syndrome but did not provide
either an estimate or a reference for the source of the
data. Gallego and colleagues [33] found three studies
showing increased risk of metabolic syndrome in APP
(without specifying individual agents) but this associ-
ation did not persist after controlling for sociodemo-
graphic and lifestyle factors.
Hyperlipidaemias
Seven reviews reported measures of lipid metabolism
[25, 27–29, 32–35]. All reported that lipid profiles were
better with APP particularly when aripiprazole was used
as the augmentation drug (n = 6).
Diabetes/ glucose metabolism disorder
Three reviews addressed these outcomes. Gallego et al.
[33] did not report any data or conclusions on glucose
levels or diabetes but reported that APP was associated
with diabetes. The other two reviews reported measures
of glucose metabolism [29, 34] where one [29] found a
small non-significant improvement in HbA1C levels in
APP involving aripiprazole compared to monotherapy
and the other [34] a non-significant decrease in glucose
levels with APP involving aripiprazole.
Hypertension
Only one review provided information on hypertension
[32] and reported that the effect of APP on hypertension
was the same as monotherapy.
Certainty of evidence
Applying GRADE criteria to our included reviews we
found that the evidence for all the outcomes was very
low quality meaning that the evidence is very uncertain.
(See Table 4).
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Discussion
Twelve studies fulfilled the criteria for this review of
reviews. This is a large body of evidence indicating
the degree of continued interest in the topic of anti-
psychotic polypharmacy in people with schizophrenia.
In the context where there are strong opposing opin-
ions about whether APP is harmful or beneficial, this
extensive body of work shows researchers’ commit-
ment to confirm through science what may be seen
as an intuitive therapeutic approach.
Overall, our findings are in line with several of the in-
cluded reviews – namely that there is insufficient
evidence to clearly answer the questions on the efficacy
and potential harms of APP.
In general, the quality of evidence was found to be
low. This was in part likely to be due to limitations in
primary studies included in the reviews. Most reviews
did not include a synthesis of findings (either as a
meta-analysis or a narrative synthesis) and only provided
descriptions of included studies. However, where the
study findings were pooled in reviews, the ranges and
confidence intervals around the effect were wide, indi-
cating uncertainty. Most reviews also did not include
studies from the grey literature and did not assess
Table 2 Quality of included systematic reviews (AMSTAR)
Review ID
AMSTAR Questions
Galling
et al.
2016
[32]
Young
et al.
2015
[25]
Tranulis
et al.
2008
[26]
Tracy
et al.
2013
[27]
Anonymous
2012
Zheng
et al.
2016
[24]
Mizuno
et al.
2014
[29]
Lerner
et al.
2004
[31]
Srisurapanont
et al. 2015
[28]
Gallego
et al.
2012
[33]
Lochmann
van
Bennekom
et al. 2013
[30]
Correll
et al.
2013
[34]
Was an ‘a priori’
design provided?
N N N Y Y Y Y N U N N U
Was there duplicate
study selection and
data extraction?
N N N N Y N Y N N N N U
Was a comprehensive
literature search
performed?
N N N Y Y Y Y N Y N N U
Was the status of
publication (i.e. grey
literature) used as an
inclusion criterion?
N N N Y Y N Y N Y N N U
Was a list of studies
(included and
excluded) provided?
N N N N N N N N N N N U
Were the
characteristics of the
included studies
provided?
Y N N Y N Y Y Y Y N N U
Was the scientific
quality of the
included studies
assessed and
documented?
N Y N N Y Y U N Y N N U
Was the scientific
quality of the
included studies used
appropriately in
formulating
conclusions?
N N N N Y Y Y N Y N N U
Were the methods
used to combine the
findings of studies
appropriate?
Y N N/A N/A Y Y Y N/A Y N/A N/A U
Was the likelihood of
publication bias
assessed?
Y N N N N Y Y N Y N N U
Was the conflict of
interest included?
N N N N N N N N N N N U
N/A Not applicable, N No, U unclear, Y Yes. Note: for Correll et al. 2013 no full text was found so assessments based on abstract only
Ijaz et al. BMC Psychiatry  (2018) 18:275 Page 8 of 13
publication bias. While five reviews compared APP to
antipsychotic monotherapy explicitly, some of the re-
views did not report their comparisons. Evidence on
hypertension was limited (one review) and for all other
outcomes the findings were heterogeneous across
reviews.
With the exception of combinations involving aripi-
prazole, it was not possible to ascertain whether some
combinations of antipsychotics were less harmful than
others, or if associations of first generation with second
generation antipsychotics had a differential effect on the
selected outcomes. Six reviews [27–29, 32–34] suggested
a protective effect of antipsychotic combinations which
included aripiprazole for dyslipidaemia and glucose me-
tabolism, compared to other combinations and/or
monotherapy. Given the quality of evidence it would be
Table 3 Metabolic effects of APP for schizophrenia reported in included reviews
Review ID Outcome measure Findings reported Interpretation
Metabolic syndrome
Gallego 2012 [33] Metabolic syndrome No synthesis or conclusion
reported for this outcome
Not applicable (comparison not specified)
Young 2015 [25] Proportion with
Metabolic syndrome
in APP users
No synthesis or data reported. They report that there is an association
between metabolic syndrome and APP but no data
reported.
Lipid profile outcomes
Galling 2016 [32] Mean Total
cholesterol mg/dl
SMD −0.27 (95%CI -0.43, −0.10) APP was associated with lower total and LDL cholesterol
compared to monotherapy
Mean LDL mg/dl SMD −0.28 (95%CI -0.45, −
0.11)
Canadian Agency for Drugs
and Technologies in Health
2012 [35]
Mean Total
cholesterol
Total cholesterol statistically
significantly lower with
Clozapine +AP
Adding a second antipsychotic to clozapine was associated
with lower total and LDL cholesterol compared to
monotherapy with clozapine.
Mean LDL LDL statistically significantly
lower with Clozapine +AP
Tracy, 2013 [27] NR Aripiprazole co-treatment
reregulates lipid profiles
APP including aripiprazole is associated with good lipid
profile (comparison not specified)
Srisurapanont, 2015 [28] Mean LDL mg/dl MD −11.06 (95%CI -18.25,
−3.87)
Aripiprazole + clozapine APP was associated with lower total
and LDL cholesterol compared to monotherapy with
clozapine
Mizuno, 2014 [29] Mean Total
cholesterol mg/dl
MD −12.81 (95%CI -19.35,
−6.27)
Mean LDL mg/dl MD − 11.69 (95% CI -19.12,
−4.26
Gallego, 2012 [33] NR Aripiprazole augmentation was
associated with a decrease in
dyslipidaemia
APP with aripiprazole is associated with good lipid profile
(comparison not specified)
Correll, 2013 [34] Mean Total
cholesterol
SMD −0.4 (95% CI -0.7,-0.2) APP with aripiprazole was associated with lower triglycerides,
and total and LDL cholesterol but not HDL cholesterol,
compared to clozapine or olanzapine monotherapy
Mean LDL SMD −0.3 (CI -0.6,- 0.1)
Mean triglycerides SMD −0.4 (CI -0.7,- 0.0)
HDL level Mean NR; p = 0.95
Glucose profile outcomes
Mizuno, 2014 [29] Mean HbA1C MD −0.65 (95%CI -1.25, − 0.06) APP with aripiprazole is associated with lower HbA1C levels
than AP monotherapy
Correll, 2013 [34] Decrease in glucose
levels
Mean NR; p = 0.41 APP with aripiprazole was associated with no significant
change in glucose levels compared to clozapine or
olanzapine monotherapy
Gallego, 2012 [33] NR No synthesis or data reported. APP has been associated with Increased diabetes.
Hypertension
Galling 2016 [32] Hypertension
(not defined)
SMD/RR (not defined): 0.97,
95%CI 0.32 to 2.98, p = 0.97
No conclusions drawn. Data indicate no difference between
AP monotherapy and APP with D2 antagonists
dl decilitre, HbA1C glycated haemoglobin, HDL High Density Lipoprotein, LDL Low density Lipoproteins, MD mean difference, mg milligram, NR not reported, NNT
numbers needed to treat; p probability value, RR Risk Ratio, SMD standardised mean difference
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premature to conclude that in the presence of another
antipsychotic, aripiprazole protects against the risk of
metabolic syndrome. Yet, the findings raise an intriguing
hypothesis that warrants further investigation into why
risks associated with combinations containing aripipra-
zole differ from those containing other commonly used
atypical antipsychotics. The relationship between an
antipsychotic drug’s mechanism or receptor binding pro-
file and metabolic syndrome is thought to be very com-
plex, and likely to be multifactorial, perhaps involving
interplay of dopamine, histamine, orexigenic neuropep-
tides, adrenergic and muscarinic receptors, and failed
glucose homeostasis, with other risk factors [37].
While aripiprazole differs from other established atyp-
ical antipsychotics by being a partial agonist at the dopa-
mine D2 receptor, the possibility of reduced risk of
metabolic syndrome in combination treatment may re-
late to its action on the serotonin system rather than the
dopamine system. One area which has received much at-
tention for atypical antipsychotics known to carry a rela-
tively high risk of metabolic complications, such as
clozapine and olanzapine, is their high affinity for sero-
tonin 5-HT2C receptors. It has been postulated [38] that
while aripiprazole acts on orexin and histamine systems
that might be protective, its key pharmacological prop-
erty may be its partial agonist activity at the serotonin
5-HT1A receptor which may counterbalance the prob-
lematic effects exerted through the 5-HT2C receptor.
This benefit would apply not only in offsetting its own
actions on 5-HT2C, but also those of co-prescribed anti-
psychotics with high affinity for this receptor.
No synthesis of effects considering dose equivalents of
antipsychotics was found. The use of dose equivalents
allows for comparison of dosage between different drugs.
It is possible that APP is only harmful relative to mono-
therapy when the final equivalent dose is excessive and
not when it is kept within established therapeutic ranges
[13]. Some reviews [28, 31–33, 35] addressed APP which
included clozapine. Clozapine can cause leukopenia [39]
and should only be used after an ineffective trial with
two other antipsychotics [8]. Furthermore, people
treated with clozapine combinations have more chronic
illness than other patients because they are considered
to be treatment-resistant, and this factor may confound
the occurrence of poorer physical health outcomes
within this sub-group.
Limitations
We searched multiple databases and employed comple-
mentary approaches to ensure no relevant published re-
views were missed. The relatively large number of
reviews detected indicates that this is an active research
area. Our inclusion and search criteria were broad and
therefore include heterogeneous patient populations,
APP interventions (combinations), comparators and
study designs. While this makes our findings
generalizable, these should be interpreted with caution
due to the limited data and quality of the included re-
views. For example, the lack of uniform comparisons
with monotherapy (specific AP drug, any AP drug, atyp-
ical or typical AP) added to problems interpreting the
findings of the same outcomes across reviews. Including
Table 4 GRADE table for APP compared to Antipsychotic monotherapy for metabolic effects in schizophrenia
GRADE assessment
Outcome № of
reviews
Risk of
bias
Inconsistency Indirectness Imprecision Other considerations GRADE Quality
rating
Metabolic
syndrome
2 Seriousa Seriousb Seriousb Seriousb Publication bias strongly suspectedc ⊕◯◯◯ VERY LOW
Lipid disorder 8 Seriousa Not serious Seriousd Seriouse Publication bias strongly suspectedf ⊕◯◯◯ VERY LOW
Diabetes 3 Seriousa Seriousg Seriousd Seriouse Publication bias strongly suspected strong
associationh
⊕◯◯◯ VERY LOW
Hypertension 1 Seriousa Not serious Not serious Seriouse Publication bias strongly suspectedi ⊕◯◯◯ VERY LOW
Explanations
aAll included reviews were low quality based on AMSTAR. Not all reviews included RCTs alone, and not all performed quality assessment of the included studies.
Primary studies were short term, small and often uncontrolled
bOnly one review reported findings but without data on direct comparison
cNone of the two reviews searched for unpublished studies or assessed publication bias
dReviews used various comparisons (before and after; one time prevalence; specific combinations of antipsychotic versus any antipsychotic)
eWide confidence intervals and/or ranges
fOnly two reviews searched for unpublished studies and none assessed publication bias
gReview findings were contrasting
hOnly one review searched for unpublished studies. None assessed publication bias
iOnly one review reported on this outcome which did not report a search for unpublished studies nor assessed publication bias for this outcome
Grade evidence levels
High = Further research is very unlikely to change our confidence in the estimate of effect
Moderate = Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low = Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low = Any estimate of effect is very uncertain
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a broad range of systematic reviews provides a more
complete picture than a single systematic review and
also allows examination of any conflicting findings
across this evidence base [40].
There was no evidence from the reviews on combina-
tions involving other atypical drugs that might theoretic-
ally present a lower risk for metabolic syndrome, such as
the second generation antipsychotics ziprasidone, asena-
pine, lurasidone and the recently introduced ‘third gen-
eration antipsychotic’ brexpiprazole. Most of these
medications are relatively new in the market and more
time may be needed until relevant reviews reach the
publication stage. Since we did not search for primary
studies we are not able to say with certainty whether this
is an overlooked area in systematic reviews or in empir-
ical research. This gap in evidence needs addressing in
future to enable robust comparisons of atypical drugs
available today.
Primary-care is an important part of the care pathway
for schizophrenia where most stable patients are man-
aged [41], although most prescribing of both anti-
psychotic monotherapy and poly-therapy is initiated in
secondary care. None of the included reviews reported
results separately by setting (primary and secondary).
This an important gap in the evidence. Primary-care
data has been used recently in long term follow up stud-
ies of psychosis treatment [42–49], however, none ad-
dressed APP and its consequences.
The evidence appeared to be of low quality for all out-
comes (Table 4), partly because of the high risk of meth-
odological and publication bias and also because the
effects of APP were variable across reviews.
Although we searched for grey literature we did not
request unpublished reviews or missing data from au-
thors, which limits the comprehensiveness of our re-
view especially if negative or inconclusive reviews are
not published [50, 51]. Furthermore, we did not t
search regional databases and therefore some poten-
tially eligible reviews that are not indexed in major
international databases may have been missed. How-
ever, considering the limitations in included reviews
we consider that unpublished or missed reviews, if
any, would also suffer from the same limitations due
to the low quality primary studies. Due to the same
limitations we did not pool results of the reviews sta-
tistically [52]. The lack of summarised or individual
study data in full, prevented us from carrying out any
additional analyses. In addition, the synthesis of re-
view level data is complex and requires careful con-
sideration of overlap of primary studies included in
several reviews and this is not always possible or
practical [40]. Therefore, we refrained from
re-analysis and only relied on a narrative synthesis to
derive our conclusions.
Based on the current evidence, we cannot definitively
conclude that APP increases the risk for metabolic syn-
drome in schizophrenia, nor that it is safe, relative to
antipsychotic monotherapy. It is imperative that this
question is investigated in a robust prospective study be-
fore any key clinical recommendations are made. Future
empirical studies should include sufficiently powered
samples and adequate follow up periods with clearly de-
fined comparison groups and outcomes to identify at
risk subgroups and whether safer regimens for schizo-
phrenia exist. Until better evidence is available, we ad-
vise that clinicians should err on the side of caution
when considering prescribing APP.
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